Old Web
English
Sign In
Acemap
>
authorDetail
>
David Robert Micklem
David Robert Micklem
University of Texas Southwestern Medical Center
Cancer research
Medicine
AXL Inhibitor BGB324
Immunology
Epidermal growth factor receptor
4
Papers
5
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Tilvestamab, a novel clinical stage humanized anti-AXL function blocking antibody
2020
European Journal of Cancer
Magnus Blø
L. Hodneland Nilsson
A. Jackson
A. Boniecka
Jason E. Toombs
Lavina Ahmed
P.M. Mydel
H.P. Marti
Rolf A. Brekken
Hani Gabra
James Bradley Lorens
David Robert Micklem
Gro Gausdal
Show All
Source
Cite
Save
Citations (0)
ANTICORPS ANTAGONISTES ANTI-AXL
2017
David Robert Micklem
Sergej Kiprijanov
James Lorens
Lavinia Ahmed
Linn Hodneland Nilsson
Tone Sandal
Show All
Source
Cite
Save
Citations (0)
Abstract B30: Selective small molecule AXL inhibitor BGB324 overcomes acquired drug resistance in non-small cell lung carcinoma models.
2014
Clinical Cancer Research
Katarzyna Wnuk-Lipinska
Gro Gausdal
Tone Sandal
Robin E. Frink
Stefan Hinz
Monica Hellesøy
Lavina Ahmed
Hallvard Haugen
Liang Xiao
Magnus Blø
David Robert Micklem
John D. Minna
Rolf A. Brekken
Longen Zhou
James Lorens
Show All
Source
Cite
Save
Citations (5)
Procédés pour créer et identifier des éléments d'interférence avec des arn fonctionnels
2008
David Robert Micklem
James Lorens
Show All
Source
Cite
Save
Citations (0)
1